Enzo Biochem, Inc. (ENZ) Surges to 52-Week High, Is Now Top Performer

June 20, 2017 - By Marguerite Chambers

Investors sentiment increased to 1.29 in 2016 Q4. Its up 0.05, from 1.24 in 2016Q3. It is positive, as 9 investors sold Enzo Biochem, Inc. shares while 29 reduced holdings. 13 funds opened positions while 36 raised stakes. 23.43 million shares or 0.05% more from 23.42 million shares in 2016Q3 were reported.
Bnp Paribas Arbitrage has 0% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 554 shares. Focused Wealth Management reported 110 shares or 0% of all its holdings. Rhumbline Advisers accumulated 0% or 42,770 shares. Zacks Mngmt holds 0.01% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 55,706 shares. Clearbridge Invs Limited Liability Company stated it has 329 shares or 0% of all its holdings. 14,000 were accumulated by Maple Mngmt. Tiaa Cref Invest Ltd accumulated 314,768 shares. Fuller Thaler Asset, California-based fund reported 9,300 shares. Amer Gp has invested 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). Tci Wealth holds 0% or 498 shares. Moreover, Bridgeway Capital Mgmt Inc has 0.03% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 322,700 shares. Panagora Asset Mngmt Inc owns 232,302 shares. Citadel Advsrs Ltd Company reported 40,231 shares stake. Moreover, Blackrock Inc has 0% invested in Enzo Biochem, Inc. (NYSE:ENZ). Acadian Asset Mgmt Lc holds 0.04% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 1.20M shares.

Since June 13, 2017, it had 0 buys, and 1 sale for $160,054 activity.

The stock of Enzo Biochem, Inc. (NYSE:ENZ) hit a new 52-week high and has $11.58 target or 7.00 % above today’s $10.82 share price. The 7 months bullish chart indicates low risk for the $514.70 million company. The 1-year high was reported on Jun, 20 by Barchart.com. If the $11.58 price target is reached, the company will be worth $36.03M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

About 81,880 shares traded. Enzo Biochem, Inc. (NYSE:ENZ) has risen 44.32% since June 20, 2016 and is uptrending. It has outperformed by 27.62% the S&P500.

More notable recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Law360.com which released: “Enzo, Yale Push To Revive $61M Patent Award Over DNA Tech” on June 05, 2017, also Seekingalpha.com with their article: “Enzo Biochem’s (ENZ) on Q2 2017 Results – Earnings Call Transcript” published on March 14, 2017, Nasdaq.com published: “Enzo Biochem (ENZ) Looks Good: Stock Jumps 13.3% in Session” on June 12, 2017. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) were released by: Businesswire.com and their article: “Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2017 Results …” published on June 02, 2017 as well as Seekingalpha.com‘s news article titled: “Enzo Biochem’s (ENZ) Q3 2017 Results – Earnings Call Transcript” with publication date: June 09, 2017.

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce services and products. The company has market cap of $514.70 million. The Company’s divisions include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. It has a 15.2 P/E ratio. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.